Novel drug may extend womens' fertility by 6 years

Researchers have identified a drug that extends egg viability in worms, even when taken midway through the fertile window, which could potentially extend a woman's fertility by three to six years.

"One of the most important characteristics of ageing is the loss of reproductive ability in mid-adulthood," said Coleen Murphy, Professor at the Princeton University in the US.

"As early as the mid-30s, women start to experience declines in fertility, increased rates of miscarriage and maternal age-related birth defects. All of these problems are thought to be caused by declining egg quality, rather than a lack of eggs," Murphy added.

The team used a microscopic worm, Caenorhabditis elegans (C.elegans), as they share many of the genes as humans, including longevity genes.

They found that a group of proteins called Cathepsin B proteases "downregulate", or lead to lower-quality oocytes (unfertilised eggs), as one ages.

In the study, published in the journal Current Biology, when the team administered the Cathepsin B inhibitor halfway through the worms' reproductive period, they found that even a late administration of the drug could extend the worms' egg quality.

Another experiment that knocked out the cathepsin B genes entirely succeeded in extending worms' fertility by about 10 per cent.

If applied to humans, Nicole Templeman from the varsity said, "It could be a three- to six-year extension of your reproductive period".

Reproductive decline is a hallmark of ageing, but despite its prevalence, interventions to slow the loss of reproductive capacity are lacking, researchers said.

However, the cathepsin B inhibitor is nowhere near ready for testing in humans, Murphy said, yet it could one day do something mid-reproduction to improve the rest of reproduction.

--IANS

rt/nks/dg


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel